2021 DORIS definition of remission in SLE: final recommendations from an international task force
Carregando...
Citações na Scopus
100
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMJ PUBLISHING GROUP
Autores
VOLLENHOVEN, Ronald F. van
BERTSIAS, George
DORIA, Andrea
ISENBERG, David
MORAND, Eric
PETRI, Michelle A.
PONS-ESTEL, Bernardo A.
RAHMAN, Anisur
UGARTE-GIL, Manuel Francisco
VOSKUYL, Alexandre
Citação
LUPUS SCIENCE & MEDICINE, v.8, n.1, article ID e000538, 8p, 2021
Resumo
Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.
Palavras-chave
lupus erythematosus, systemic, outcome assessment, healthcare, therapeutics
Referências
- Alarcon GS, 2019, LUPUS, V28, P423, DOI 10.1177/0961203319826693
- Ugarte-Gil MF, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-000955
- Ugarte-Gil MF, 2017, ANN RHEUM DIS, V76, P2071, DOI 10.1136/annrheumdis-2017-211814
- Kandane-Rathnayake R, 2019, INT J RHEUM DIS, V22, P425, DOI 10.1111/1756-185X.13431
- Petri M, 2018, ARTHRITIS RHEUMATOL, V70, P1790, DOI 10.1002/art.40571
- Pons-Estel G, 2020, ARTHRITIS RHEUMATOL, V72
- Reategui-Sokolova C, 2019, LUPUS, V28, P1344, DOI 10.1177/0961203319876998
- Saccon F, 2020, ANN RHEUM DIS, V79, P943, DOI 10.1136/annrheumdis-2020-217070
- Tsang-A-Sjoe MWP, 2019, RHEUMATOLOGY, V58, P628, DOI 10.1093/rheumatology/key349
- Tsang-A-Sjoe MWP, 2017, RHEUMATOLOGY, V56, P121, DOI 10.1093/rheumatology/kew377
- Ugarte-Gil MF, 2020, ANN RHEUM DIS, V79, P1518, DOI 10.1136/annrheumdis-2020-eular.2037
- Ugarte-Gil MF, 2020, JCR-J CLIN RHEUMATOL, V26, P69
- Ugarte-Gil MF, 2020, ARTHRIT CARE RES, V72, P1159, DOI 10.1002/acr.24009
- Ugarte-Gil MF., 2020, ARTHRITIS RHEUMATOL, V72
- van Vollenhoven R, 2019, NAT REV RHEUMATOL, V15, P180, DOI 10.1038/s41584-019-0170-5
- van Vollenhoven R, 2017, ANN RHEUM DIS, V76, P554, DOI 10.1136/annrheumdis-2016-209519
- van Vollenhoven RF, 2014, ANN RHEUM DIS, V73, P958, DOI 10.1136/annrheumdis-2013-205139
- Wilhelm TR, 2017, ANN RHEUM DIS, V76, P547, DOI 10.1136/annrheumdis-2016-209489
- Zen M, 2017, ANN RHEUM DIS, V76, P562, DOI 10.1136/annrheumdis-2016-210154
- Zen M, 2015, ANN RHEUM DIS, V74, P2117, DOI 10.1136/annrheumdis-2015-207347
- Zhang AD, 2019, RHEUM DIS CLIN N AM, V45, P505, DOI 10.1016/j.rdc.2019.07.002